Format

Send to

Choose Destination
Genes Dev. 2014 Sep 1;28(17):1917-28. doi: 10.1101/gad.245910.114.

ZBTB7A acts as a tumor suppressor through the transcriptional repression of glycolysis.

Author information

1
Department of Genetics and Complex Diseases, Harvard School of Public Health, Boston, Massachusetts 02115, USA;
2
Division of Signal Transduction, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02115, USA.
3
Department of Genetics and Complex Diseases, Harvard School of Public Health, Boston, Massachusetts 02115, USA; zyuan@hsph.harvard.edu.

Abstract

Elevated glycolysis is a common metabolic trait of cancer, but what drives such metabolic reprogramming remains incompletely clear. We report here a novel transcriptional repressor-mediated negative regulation of glycolysis. ZBTB7A, a member of the POK (POZ/BTB and Krüppel) transcription repressor family, directly binds to the promoter and represses the transcription of critical glycolytic genes, including GLUT3, PFKP, and PKM. Analysis of The Cancer Genome Atlas (TCGA) data sets reveals that the ZBTB7A locus is frequently deleted in many human tumors. Significantly, reduced ZBTB7A expression correlates with up-regulation of the glycolytic genes and poor survival in colon cancer patients. Remarkably, while ZBTB7A-deficient tumors progress exceedingly fast, they exhibit an unusually heightened sensitivity to glycolysis inhibition. Our study uncovers a novel tumor suppressor role of ZBTB7A in directly suppressing glycolysis.

KEYWORDS:

GLUT3; PFKP; PKM; ZBTB7A; glycolysis; tumor suppressor

PMID:
25184678
PMCID:
PMC4197949
DOI:
10.1101/gad.245910.114
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center